Pulsenmore

Pulsenmore EBIT CAGR 5Y

The EBIT CAGR (5 Year) of Pulsenmore (PLSM.TA) as of Oct 31, 2026 is -1.74 %. In the previous year, EBIT CAGR (5 Year) was -1.74 % — a change of 0.00% (lower).

EBIT CAGR 5Y

-1.74 %

YoY

0.00%

Last updated:

EBIT CAGR (5 Year) of Pulsenmore is 2025 -1.74 % . EBIT CAGR (5 Year) of Pulsenmore was 2024 -1.74 % . It decreases by 0.00% lower compared to the previous year.

The Pulsenmore EBIT CAGR 5Y history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT CAGR 5Y
Date
EBIT CAGR 5Y
Jan 1, 2019
-1.74 ILS
Jan 1, 2020
-1.74 ILS
Jan 1, 2021
-1.74 ILS
Jan 1, 2022
-1.74 ILS
Jan 1, 2023
-1.74 ILS
Jan 1, 2024
-1.74 ILS
Jan 1, 2025
-1.74 ILS
The Pulsenmore EBIT CAGR 5Y history
YEAREBIT CAGR 5YYoY
-1.74 %0.00%
-1.74 %0.00%
-1.74 %0.00%
-1.74 %0.00%
-1.74 %0.00%
-1.74 %0.00%
-1.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pulsenmore Stock analysis

What does Pulsenmore do? Pulsenmore Ltd. generates revenue through the sale of its two miniaturized ultrasound systems, PulseNmore ES and PulseNmore FC, designed for home use in remote clinical diagnosis. The PulseNmore ES targets pregnant women requiring regular ultrasound monitoring, while PulseNmore FC caters to women undergoing in vitro fertilization needing follicle size assessments. Both systems integrate with smartphones, enabling patients to conduct tests at home and share results online with healthcare providers. The company also monetizes through software delivery for its devices, enhancing user experience and data management. The primary buyers of PulseNmore ES are pregnant women seeking convenient, clinic-free monitoring, and healthcare providers managing prenatal care remotely. PulseNmore FC is purchased by women undergoing in vitro fertilization, often through fertility clinics or medical centers that recommend the device. These segments value the convenience of home-based diagnostics and seamless telehealth integration without requiring in-person visits. Pulsenmore Ltd. focuses on global markets for its portable ultrasound solutions, serving patients in remote or underserved areas who benefit from telehealth-enabled diagnostics. The company’s products are positioned as cost-effective alternatives to traditional clinic visits, appealing to both end-users and healthcare institutions aiming to reduce operational costs while maintaining patient care quality. Pulsenmore is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulsenmore stock

EBIT CAGR (5 Year) of Pulsenmore is -1.74 % in 2025.

On Eulerpool you can find the complete historical development of EBIT CAGR (5 Year) Pulsenmore since 2006 – with annual values, charts, and detailed analysis.

The 5-year EBIT CAGR shows the compound annual growth rate of EBIT over the past five years.

To evaluate EBIT CAGR (5 Year)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT CAGR (5 Year).

EBIT CAGR (5 Year)'s is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT CAGR (5 Year)'s Pulsenmore historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Pulsenmore

All Key Metrics — Pulsenmore